Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia.

  • Siatkowski R
  • Cotter S
  • Crockett R
 et al. 
  • 22


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


PURPOSE: To evaluate if the safety and efficacy of the relatively selective M1-antagonist, pirenzepine, in slowing the progression of myopia in children is sustained over a 2-year period. METHODS: This was a multicenter, parallel-group, placebo-controlled, double-masked, randomized clinical trial. Enrolled were children aged 8 to 12 years, with entry spherical equivalent refractive error of -0.75 to -4.00 D and astigmatism

Author-supplied keywords

  • Administration, Topical
  • Child
  • Double-Blind Method
  • Follow-Up Studies
  • Gels
  • Humans
  • Muscarinic Antagonists
  • Muscarinic Antagonists: administration & dosage
  • Myopia
  • Myopia: drug therapy
  • Myopia: physiopathology
  • Pirenzepine
  • Pirenzepine: administration & dosage
  • Refraction, Ocular
  • Refraction, Ocular: drug effects
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • R Michael Siatkowski

  • Susan a Cotter

  • R S Crockett

  • Joseph M Miller

  • Gary D Novack

  • Karla Zadnik

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free